Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.
Susana Banerjee, MBBS, PhD
Advertisement
Susan Banerjee, MBBS, PhD, is a consultant medical oncologist and research lead for the gynecology unit at the Royal Marsden, London, UK.
Articles by Susana Banerjee, MBBS, PhD
Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
3
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
4
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
5